Autoinflammatory Alliance Inc

Nonprofit profile at a glance

EIN
204915307
IRS 990-EZ coverage
2014–2025
Forms available
Form 990-EZ 2025, Form 990-N 2023
Location
San Francisco, CA, USA
Phone
4158318782
Rating
58
Verdict
MIXED
Rating confidence
Moderate
Sector
Fund Raising and/or Fund Distribution

Official website

Reported finances

Revenue
$62,992
Expenses
$38,656
Assets
$125,809
Liabilities
$0

Source: IRS Form 990-EZ. Selected filing: tax year 2025. Amounts in USD.

Leadership & pay

11 people listed

Executive titles in this filing

  • Karen Durrant (RN, president, founder, director, research lead, patient group admin and board member)
  • Dorelia Rivera (Vice President, patient advocate, policy lead, CAPS patient group moderator, board member)

People named in this filing

  • Karen Durrant (RN, president, founder, director, research lead, patient group admin and board member)
  • Nathan Durrant (secretary/treasurer, graphic PR lead, Board member)
  • Dorelia Rivera (Vice President, patient advocate, policy lead, CAPS patient group moderator, board member)

Selected names, not a complete roster or a statement of current roles. Open leadership details for the complete filed list.

Source: IRS Form 990-EZ. Selected filing: tax year 2025. Names and roles reflect this filing, not necessarily current officeholders.

Overview

Mission

Rare Disease Organization. The Autoinflammatory Alliance is a 501 (c)(3) non-profit public charity dedicated to promoting awareness, proper diagnosis and treatment, and improved care for people with autoinflammatory diseases. This includes supporting appropriate research and programs that will improve the lives of patients.

What it reported doing in 2025

Supporting Autoinflammtory Disease Research with innovative research for unmet needs. The Autoinflammatory Alliance has fundraised and worked with our scientific advisors, and also our patient community and families that have done fundraising to help determine the right programs to support for advancing care and research for systemic autoinflammatory diseases. In 2025, we were able to find the right program at the NIH NIAID Translational Autoinflammatory Research Institute Gift Fund to support research for the severe form of CAPS, including NOMID/CINCA and the new complications affecting some patients with all forms of CAPS globally that are experiencing amyloidosis induced by one of the few, or only medication to treat their form of CAPS-especially for NOMID patients that need this medication to get to the brain. The medication-induced amyloidosis is a new, and concerning issue that has been found to not only cause some lumps and tissue issues in the injection sites that can start to grow enormous in some cases, but a few are developing life limiting systemic medication induced amyloidosis. $18,000 was donated to the NIAID TARI gift fund in 2025 to directly support the research study to develop a new scanning method to check patients for this amyloidosis to see if it is in the tissues and organs in the body, since it is otherwise impossible to biopsy randomly internal organs, or all over the skin at multiple sites without a risk to patients. This scanner and future new medication trials to find another drug to treat these patients instead of this current one causing this issue were supported with this grant. In addition, $7500 was donated to start the TNFAIP3 HA20 Registry with NORD and the University of Pittsburgh, which is needed to better understand the many forms and issues that this more newly discovered disease can cause. We paid this money in 2025, and received a reimbursement for the money in 2026 from the University of Pittsburgh once they received their grant funds, and we had established this as a NORD member org. This registry will be finalized in 2026, and there will be some ongoing costs that we will support and receive some reimbursement. We are a NORD member org, and this registry with IAMRARE must be done in collaboration with researchers, our scientific advisors, and NORD, along with U Pitt researchers. These funds are being used strictly for this registry, and not financially benefitting any scientific advisor or board member of the Autoinflammatory Alliance. Total grants paid out for research in 2025= $25,500.

Operating model

Revenue model
Mixed. Its operating money came from several sources; no one source provided a clear majority.
Distribution model
Cannot be determined from the filing. The filing does not provide enough consistent spending detail to tell whether the nonprofit works directly or through others.

The verdict

MIXED - The filed numbers largely add up and revenue comfortably covers expenses. A relatively small share of available resources goes toward mission work and a relatively small share of total spending goes to programs.

Rating breakdown

  • Financial Efficiency: 26
  • Transparency & Controls: 100
  • Sustainability: 77
  • Growth: 20

Detailed rating inputs

Financial Efficiency

  • Mission deployment rate: 20.5%; rating input score 21
  • Program expense ratio: 33.4%; rating input score 33

Transparency & Controls

  • Consistency checks: 100%; rating input score 100; 51st percentile among comparable filings
  • Major donor itemization: Yes; rating input score 100

Sustainability

  • Operating margin: 38.6%; rating input score 85; 85th percentile among comparable filings
  • Total-asset coverage ratio: 3.25; rating input score 76; 76th percentile among comparable filings
  • Liabilities to assets ratio: 0; rating input score 66; 66th percentile among comparable filings
  • Officer compensation ratio: 0%; rating input score 56; 56th percentile among comparable filings

Growth

  • Program expense growth: -14.4% per year; rating input score 0; 24th percentile among comparable filings
  • Revenue growth: -7% per year; rating input score 0; 29th percentile among comparable filings
  • Asset growth: 11.1% per year; rating input score 100; 72nd percentile among comparable filings

Details

  • Where the money goes: 20.5% of revenue deployed · 33.4% of spending went to programs
  • Governance: Filed governance answers
  • Accomplishments: 3 filed program accomplishments · $13K in reported program spending
  • Leadership: top reported pay $0 · 11 people listed
  • Consistency: 8 of 9 current checks pass · 1 finding to review
  • Schedules: 4 filed schedules
  • Filing history: 7 filing years from 2014 to 2025
  • Contacts: How to reach this organization
  • Money network: Resolved incoming and outgoing counterparties from filed money flows.
  • Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
  • People: Everyone the filings name, and which of them the filings identify by more than a name.

Key Signals

Signals prioritize questions for review. They are not findings of misconduct.

  • High — Financial Efficiency: Mission deployment rate scored 21/100.
  • Moderate — Financial Efficiency: Program expense ratio scored 33/100.
  • Moderate — Transparency & Controls: Part III transfer expenses within program total did not reconcile in the filed values.
  • High — Growth: Program expense growth scored 0/100.
  • High — Growth: Revenue growth scored 0/100.
  • Review — Sustainability: Officer compensation ratio scored 56/100.